BioSpace News Archive

Oncternal Therapeutics, Inc. (Nasdaq: ONCT) today announced that the U.S. Food and Drug Administration (FDA) has designated ONCT-534, its novel dual-acting androgen receptor inhibitor (DAARI), as a Fast Track development program for the investigation of the treatment of patients with relapsed or refractory metastatic castration-resistant prostate cancer (mCRPC) resistant to approved androgen receptor pathway inhibitors (ARPIs).

Clarity Pharmaceuticals and PSI CRO AG have entered into an agreement and have commenced work towards Clarity’s Phase III diagnostic trial of SAR-bisPSMA in prostate cancer participants, CLARIFY 1.

Centinel Spine®, LLC announced that the Food and Drug Administration has accepted the filing of its Premarket Approval application submitted for the Investigational Device Exemption study evaluating the Company’s prodisc C Vivo and prodisc C SK cervical TDR system.

Elation Health, the clinical-first technology company powering innovation in primary care, announced today its plans at FMX 2023 in Chicago to discuss the highlights of a second study with the American Academy of Family Physicians (AAFP) Innovation Lab, which identifies key innovations that optimize the family medicine experience.

Alfasigma S.p.A. announced that the required waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 with respect to Alfasigma’s proposed acquisition of Intercept Pharmaceuticals, Inc. expired at 11:59 p.m. on October 25, 2023.

BioAge Labs, Inc., (“BioAge”), a clinical-stage biotechnology company developing therapeutics that target the molecular causes of aging to extend healthy human lifespan, today announced plans to initiate a Phase 2 trial of its oral apelin receptor agonist BGE-105 (azelaprag) co-administered with the GLP-1/GIP receptor agonist tirzepatide for treatment of obesity.

GE HealthCare and reLink Medical announced a collaboration to deliver asset management solutions to healthcare providers to help reduce medical device waste, increase operational efficiency and maximize their equipment utilization.

Vaccinex, Inc., a clinical-stage biotechnology company, reports novel findings for its lead product, pepinemab, in a highlighted podium presentation at the Clinical Trials on Alzheimer’s Disease Conference in Boston, MA.

Fresenius Medical Care announced the phase-one completion of the company’s first anonymized global dialysis dataset—coined the Apollo database project—the foundation of the company’s long-term AI aspirations.

Eli Lilly and Company (NYSE: LLY) will attend the UBS Biopharma Conference on Nov. 8, 2023. Patrik Jonsson, executive vice president; president, Lilly Immunology; president, Lilly USA; and chief customer officer, will participate in a fireside chat at 3 p.m., Eastern time.